Mainstay therapy of COPD and asthma include inhaled corticosteroids (ICSs). So far, available scientific data indicates the high propensity of TB infections in patients using ICSs, but very few studies have determined the non-tuberculoses infections associated with ICSs use. A recent study published in a well-known journal 'European Respiratory Journal' provided some insights in this regard. Inhaled corticosteroid (ICS) are considered mainstay therapy in COPD and asthma management.
However, as ICSs are delivered directly to the lungs and therefore asthma and COPD patients are susceptible to local infections especially tuberculosis. However, very studies have examined the potential risk of non-tuberculous mycobacterial pulmonary infections associated with ICSs use. In this regard, Canadian researchers conducted a primary study which determined if using ICSs is associated with an…
